| | Non-cirrhotic (no. = 26) | Child A (no. = 36) | Child B (no. = 18) | Test valuea | p-valuea |
---|
| Mean | ± SD | Median | Mean | ± SD | Median | Mean | ± SD | Median |
---|
IMT | Baseline | 1.18 | 0.46 | 0.95 | 1.17 | 0.32 | 1.04 | 1.46 | 0.61 | 1.42 | 4.75 | 0.093 |
6-month follow-up | 0.95 | 0.39 | 0.76 | 0.97 | 0.35 | 0.90 | 1.06 | 0.49 | 0.88 | 2.61 | 0.271 |
p-valueb | | < 0.001 | < 0.001 | 0.001 | |
- p ≤ 0.05 is considered statistically significant; p ≤ 0.01 is considered highly statistically significant. aKruskal-Wallis test. bWilcoxon signed-rank test. SD Standard deviation, IMT Intima-media thickness. IMT at baseline and 6-month follow-up after initiation of anti-HCV therapy and the presence of cirrhosis revealed that there was no significant difference between cirrhotic (neither child A nor B) and non-cirrhotic patients as regards carotid IMT at baseline and after 6-month follow-up. Meanwhile, there was significant decrease in carotid IMT at baseline compared to after 6-month follow-up in the three groups individually